Table I.

Reported adverse events and dupilumab discontinuation based on follow-up time

Variable	Follow-up periods
	0-16 weeks (N = 145)	16-52 weeks (N = 143)	52-104 weeks (N = 139)
One or more adverse event, n (%)	64 (44)	48 (34)	31 (22)
Reported adverse events, n (%)
Ocular surface disease	45 (31)	36 (25)	18 (13)
Infections	8 (6)	3 (2)	4 (3)
Oral herpes	6 (4)	1 (1)	2 (1)
Cellulitis	2 (1)	1 (1)	1 (1)
Cystitis	1 (1)	1 (1)	0
Flu-like symptoms	1 (1)	2 (1)	0
Upper respiratory tract infection	0	0	1 (1)
Skin disorders
Injection site reaction	6 (4)	2 (1)	2 (1)
Head and neck eczema flare or redness	2 (1)	4 (3)	7 (5)
Urticaria	1 (1)	2 (1)	2 (1)
Asthma flare	1 (1)	0	0
Musculoskeletal
Fatigue	1 (1)	0	0
Arthralgia	2 (1)	3 (2)	0
Headache	0	0	0
Gastrointestinal symptoms	4 (3)	2 (1)	0
Generalized nonspecific symptoms∗	4 (3)	2 (1)	0
Dupilumab discontinuation, n (%)†	5 (3)	20 (14)	9 (6)
Secondary to adverse event	4 (3)	6 (4)	4 (3)
Due to lack of efficacy	1 (1)	12 (8)	1 (1)
Non–drug-related reason‡	0	2 (1)	4 (3)

n, Number of subjects meeting criteria.

^∗Nonspecific symptoms include episodes of dizziness, lightheadedness, blurred vision, and/or sweating.

^†Patients who discontinued dupilumab due to an adverse event or lack of efficacy were carried forward and included as Investigator Global Assessment nonresponders for each timepoint. Discontinuation due to non–drug-related reasons was excluded from Investigator Global Assessment analysis.

^‡Non–drug-related reasons include pregnancy, travel, and loss of insurance drug coverage.